11:34 AM EST, 03/07/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Thursday it completed its acquisition of Ambrx Biopharma in an all-cash deal for an equity value of about $2 billion, or $1.9 billion net of estimated cash acquired.
The deal will be accounted for as a business combination, Johnson & Johnson ( JNJ ) said.
Price: 159.35, Change: +0.01, Percent Change: +0.01